Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Dec 20, 2022 1:50pm
242 Views
Post# 35182681

Just the facts…mam just the facts.

Just the facts…mam just the facts.

Oncolitics biotch is a junior research biotech company with one " drug" called Pelareorep.
aka Pela.
Onc has been in trials for over 20 years. As such & within , have proven. With 1000s of patients.
Pela only multiples in cancer cells. Making its delivery very safe.
one of very few cancer treatments that can be delivered through I.V.
giving Pela a very competitive advantage.
Does not need to be inter- Tumor delivery...it finds the cancer.
Eraly trial lead to the discovery of " turning cold tumours hot"..meaning your immune system can see the tumour, which previously was hidden.
Recent trials ( all co- therapy), with Roche, Pfizer, Incyte, B.m.s. & Merck; All are looking to identify efficacy & improments or expansion of their existing markets.
Pela for example, Can exapand an existing patient base of response by multiples....by lighting up the tumour.
In 2017, a mbreast cancer trail showed results leading to a partnership with A.N. 
Most recently a co- therapy trial with Roche, demonstrated amazing results. With a very hard to treat pancreatic cancer.
That was significant enough to bring about FDA fast track designation, in a matter of a few months.
A few take to heart to attack me. Yet, I am meaningless. 

What is important are the development facts TODAY, 
Roche, Pfizer, Incyte, Merck ...would never put there good names or drugs on the line without Wide & deep resurch.
The panc results for example with Tecentriq, a lead cancer & standard of care.
Roche would never risk the good name of the drug or their company without muktiple due diligence.
Both for Pela & ONC as a company.
so throwing random statements out based on share price activity, is very miss information.
so again a challenge to anyone who is so well informed. Please let the executives of the above mentioned worlD leader pharma companies.your astute information that they are all wasting their time.
bottom line 
onc has had a long journey.
now they have great collaborations to assist in the journey.
should they sucseed . Oncolitics biotech will be worth billions.
should they fail, not much less then now.

 



 

<< Previous
Bullboard Posts
Next >>